Skip to Content

Fidelity Advisor Biotechnology M FBTTX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 25.89  /  +0.15 %
  • Total Assets 1.6 Bil
  • Adj. Expense Ratio
    1.290%
  • Expense Ratio 1.290%
  • Distribution Fee Level Average
  • Share Class Type Front Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.91%
  • Turnover 78%

USD | NAV as of May 24, 2024 | 1-Day Return as of May 24, 2024, 10:12 PM GMT+0

Morningstar’s Analysis FBTTX

Will FBTTX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Advisor Biotechnology M’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTTX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 63.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

24.05 434.9 Mil
Healthcare

Amgen Inc

9.45 170.9 Mil
Healthcare

Regeneron Pharmaceuticals Inc

7.82 141.3 Mil
Healthcare

Ascendis Pharma A/S ADR

3.97 71.8 Mil
Healthcare

Vertex Pharmaceuticals Inc

3.64 65.8 Mil
Healthcare

Alnylam Pharmaceuticals Inc

3.31 59.9 Mil
Healthcare

Viking Therapeutics Inc

3.25 58.8 Mil
Healthcare

Cytokinetics Inc

3.12 56.5 Mil
Healthcare

argenx SE ADR

2.28 41.3 Mil
Healthcare

Vaxcyte Inc Ordinary Shares

2.26 40.9 Mil
Healthcare